Francesco Montorsi

Featured in: Favicon

wiley.com (+1) Favicon

corriere.it Favicon

jamanetwork.com Favicon

thelancet.com Favicon

unirioja.es Favicon

futuremedicine.com Favicon

europeanurology.com (+1) Favicon

bjuinternational.com Favicon

dialnet.unirioja.es

Articles

Re: Metastatic Hormone-sensitive Prostate Cancer and Combination Treatment Outcomes: A Review

Jan 10, 2025 | europeanurology.com | Mattia Longoni |Alberto Briganti |Giorgio Gandaglia |Francesco Montorsi

Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aUnit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Lab, IRCCS San Raffaele Scientific Institute, Milan, Italy b“Vita-Salute” San Raffaele University, Milan, Italy Publication History: Accepted January 2, 2025; Published online January 10,...
Les origines de l'armorial de la Table Ronde

May 28, 2024 | dialnet.unirioja.es | Francesco Montorsi

IdiomacatalàDeutschEnglishespañoleuskarafrançaisgalegoitalianoportuguêsromână
Maria Teresa Rachetta, L'Histoire ancienne jusqu'à César. Saggio di storia della cultura francofona del XIII secolo. Roma, Viella, 2022 [I libri di Viella, 435]

May 28, 2024 | dialnet.unirioja.es | Francesco Montorsi

Maria Teresa Rachetta, L'Histoire ancienne jusqu'à César. Saggio di storia della cultura francofona del XIII secolo. Roma, Viella, 2022 [I libri di Viella, 435]Localización: Romania: revue trimestrielle consacré a l'étude des langues et des littératures romanes, ISSN 0035-8029, Tome 141, Nº 3-4, 2023, págs. 482-486Idioma: francésEs reseña de: L'Histoire ancienne jusqu'à César.
Current Standards for Training in Robot-assisted Surgery and Endourology: A Systematic Review

Apr 22, 2024 | europeanurology.com | Giuseppe Basile |Andrea Gallioli |Humanitas Clinical |Anthony Gallagher |Pietro Diana |Alessandro Larcher | +9 more

AbstractDifferent training programs have been developed to improve trainee outcomes in urology. However, evidence on the optimal training methodology is sparse. Our aim was to provide a comprehensive description of the training programs available for urological robotic surgery and endourology, assess their validity, and highlight the fundamental elements of future training pathways. We systematically reviewed the literature using PubMed/Medline, Embase, and Web of Science databases.
Re: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Feb 17, 2024 | europeanurology.com | Marco Moschini |Andrea Necchi |Francesco Montorsi

Galsky MD, Daneshmand S, Izadmehr S, et alTo read this article in full you will need to make a paymentSubscribe to European UrologyReferencesEuropean Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol.
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study

Mar 24, 2023 | europeanurology.com | Marco Moschini |Andrea Salonia |Alberto Briganti |Francesco Montorsi

Results from HIVEC-II for Intermediate-risk Non–muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
Re: A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer

Feb 16, 2023 | europeanurology.com | Mario de Angelis |Alberto Briganti |Francesco Montorsi |Marco Moschini

• None Maintenance versus non-maintenance intravesical bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized clinical trials. :• None Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non-muscle-invasive bladder cancer: a systematic review and network meta-analysis of randomized trials. :
Re: Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors. A P

Feb 16, 2023 | europeanurology.com | Marco Moschini |Francesco Montorsi

To read this article in full you will need to make a payment
Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80 - European Urology

Feb 9, 2023 | europeanurology.com | Francesco Montorsi |Simone Scuderi |Alberto Briganti |Giorgio Gandaglia

We read with interest the Platinum Opinion by Schilham et al. [] on how advanced imaging modalities might solve the current diagnostic challenges for patients with prostate cancer (PCa). Although we agree with the authors that new imaging techniques will overcome the limitations of conventional approaches and will play a major role soon, some points warrant further attention.
Re: Kerrington Powell, Michael C. Burns, Vinay Prasad. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. Eur Urol. 2023;83:101-2 - European Urology

Feb 9, 2023 | europeanurology.com | Francesco Montorsi |Simone Scuderi |Alberto Briganti |Giorgio Gandaglia

We read with interest the editorial by Powell et al. [] questioning the recent approval by the US Food and Drug Administration and the European Medicines Agency of the first oral gonadotropin-releasing hormone (GnRH) antagonist relugolix for the treatment of patients with advanced prostate cancer (PCa) [].

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →